Scienta is a deeptech company advancing translational research in immunology.

We develop EVA, the first AI foundation model purpose-built for translational prediction in immune-mediated diseases. EVA addresses one of the biggest challenges in pharma R&D: the preclinical–clinical gap, where fewer than 10% of immune drug programs successfully translate to humans. Our mission is to bring predictive clarity to this high-risk phase of development.

Built on more than 3 billion multimodal data points across 30 diseases and 70 tissues, EVA is designed to reason like an immunologist. Its biology-first architecture translates early experimental signals into predicted patient outcomes, with explainable outputs such as pathway-level activity and mechanism-linked biomarkers that directly inform R&D decisions.

Our approach is scientifically validated. In inflammatory bowel disease, EVA accurately replicated anti-TNF clinical trial outcomes using only preclinical and baseline transcriptomic data, outperforming existing academic and private models. Our work is backed by 18 peer-reviewed publications and 2 patents.

Located at BioLabs Hôtel-Dieu (Paris), Scienta is supported by leading investors, was selected among Station F’s Future 40, and named a laureate of the EIC Accelerator. Our team brings together AI, immunology, and pharma expertise, with a strong PhD backbone.

If you want to work on hard scientific problems with real impact, you’ll feel at home at Scienta!